CompletedPhase 2NCT00483067

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

Studying Hypereosinophilic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Michael Andreeff, MD, PhD
M.D. Anderson Cancer Center
Intervention
2-CdA(drug)
Enrollment
13 enrolled
Eligibility
76 years · All sexes
Timeline
19982008

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00483067 on ClinicalTrials.gov

Other trials for Hypereosinophilic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypereosinophilic syndrome

← Back to all trials